Skip to main navigation

English
Français

IR Navigation

Overview
News
Events & Presentations
- Events
- Presentations
Stock Information
Financials
Governance
Resources

Press Releases

Press Releases

Year

25 May 2026

GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026

21 May 2026

GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update

11 May 2026

GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents

20 Apr 2026

GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)

07 Apr 2026

GENFIT Announces Publication of the 2025 Universal Registration Document

02 Apr 2026

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

09 Mar 2026

GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF

26 Feb 2026

GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update

12 Feb 2026

GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales

13 Jan 2026

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

07 Jan 2026

GENFIT Announces 2026 Financial Calendar

06 Jan 2026

GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N

Shareholder Tools

Print Page
Email Alerts
RSS
Contact IR

Request E-mail Alerts

GENFIT Headquarters
Parc Eurasanté 885, Avenue Eugène Avinée 59120 Loos France GENFIT Corp
185 Alewife Brook Parkway, #210 Cambridge, MA 02138 VERSANTIS AG
Technoparkstrasse 1, 8005 Zürich, Suisse

All rights reserved.